ArticlePloS one2010
Expanding the substantial interactome of NEMO using protein microarrays.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Identification of novel candidate biomarkers for heart failure with preserved ejection fraction by the Olink proteomics platform.International journal of cardiology. Heart & vasculature · 2026Article
- A Thermodynamic Model for Interpreting Tryptophan Excitation-Energy-Dependent Fluorescence Spectra Provides Insight Into Protein Conformational Sampling and Stability.Frontiers in molecular biosciences · 2021Article
- TheFrontiers in molecular neuroscience · 2021Article
- Article
- Cholesterol restricts lymphotoxin β receptor-triggered NF-κB signaling.Cell communication and signaling : CCS · 2019Article
- The Prognostic Significance of Eukaryotic Translation Initiation Factors (eIFs) in Endometrial Cancer.International journal of molecular sciences · 2019Article
- Placental Expression of NEMO Protein in Normal Pregnancy and Preeclampsia.Disease markers · 2019Article
- Central catalytic domain of BRAP (RNF52) recognizes the types of ubiquitin chains and utilizes oligo-ubiquitin for ubiquitylation.The Biochemical journal · 2017Article
- ArfGAP Domain-Containing Protein 2 (ADAP2) Integrates Upstream and Downstream Modules of RIG-I Signaling and Facilitates Type I Interferon Production.Molecular and cellular biology · 2017Article
- Characterization and Genetic Analyses of New Genes Coding for NOD2 Interacting Proteins.PloS one · 2016Article
- LRRK2 Pathways Leading to Neurodegeneration.Current neurology and neuroscience reports · 2015Review
- Polyubiquitin Drives the Molecular Interactions of the NF-κB Essential Modulator (NEMO) by Allosteric Regulation.The Journal of biological chemistry · 2015Article
- Human genome-wide RNAi screen identifies an essential role for inositol pyrophosphates in Type-I interferon response.PLoS pathogens · 2014Article
- Gene expression modifications in Wharton's Jelly mesenchymal stem cells promoted by prolonged in vitro culturing.BMC genomics · 2013Article
- Natural selection in a bangladeshi population from the cholera-endemic ganges river delta.Science translational medicine · 2013Article
- Modulation of mitogen-activated protein kinase-activated protein kinase 3 by hepatitis C virus core protein.Journal of virology · 2013Article
- Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase.Protein & cell · 2013Review
- Article
- Article
- Histamine-releasing factor has a proinflammatory role in mouse models of asthma and allergy.The Journal of clinical investigation · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signal transduction by the NF-kappaB pathway is a key regulator of a host of cellular responses to extracellular and intracellular messages. The NEMO adaptor protein lies at the top of this pathway and serves as a molecular conduit, connecting signals transmitted from upstream sensors to the downstream NF-kappaB transcription factor and subsequent gene activation. The position of NEMO within this pathway makes it an attractive target from which to search for new proteins that link NF-kappaB signaling to additional pathways and upstream effectors. In this work, we have used protein microarrays to identify novel NEMO interactors. A total of 112 protein interactors were identified, with the most statistically significant hit being the canonical NEMO interactor IKKbeta, with IKKalpha also being identified. Of the novel interactors, more than 30% were kinases, while at least 25% were involved in signal transduction. Binding of NEMO to several interactors, including CALB1, CDK2, SAG, SENP2 and SYT1, was confirmed using GST pulldown assays and coimmunoprecipitation, validating the initial screening approach. Overexpression of CALB1, CDK2 and SAG was found to stimulate transcriptional activation by NF-kappaB, while SYT1 overexpression repressed TNFalpha-dependent NF-kappaB transcriptional activation in human embryonic kidney cells. Corresponding with this finding, RNA silencing of CDK2, SAG and SENP2 reduced NF-kappaB transcriptional activation, supporting a positive role for these proteins in the NF-kappaB pathway. The identification of a host of new NEMO interactors opens up new research opportunities to improve understanding of this essential cell signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.